

XXXIII CONGRESSO NAZIONALE AIRO

AIRO2023

BOLOGNA,
27-29 OTTOBRE 2023

PALAZZO DEI CONGRESSI

Radioterapia Oncologica: l'evoluzione al servizio dei pazienti



Associazione Italiana
Radioterapia e Oncologia clinica

XXXIII CONGRESSO NAZIONALE AIRO

AIRO2023

BOLOGNA,
27-29 OTTOBRE 2023

PALAZZO DEI CONGRESSI

Radioterapia Oncologica: l'evoluzione al servizio dei pazienti


SAFETY AND EFFICACY OF RADIOLIGAND THERAPY WITH LUTETIUM-177- PSMA-617 IN A PATIENT WITH METASTATIC PROSTATE CANCER

Sara Talomo
Istituto Oncologico Veneto (Padova)

RADIOLIGAND THERAPY (RLT) with Lutetium 177 prostate-specific membrane antigen-617 (^{177}Lu -PSMA-617)

WHO: Patients with progressive metastatic castration resistant prostate cancer (mCRPC) after standard therapy

HOW: PSMA-targeted ligands are conjugated to radioactive isotopes to deliver beta-particle radiation selectively to PSMA-positive cells (like PC ones) and surrounding microenvironment.



Our patient: In 2010 (58 years-old) diagnosis of prostate cancer with bone metastases

Treatments:

radical prostatectomy, LHRH analogue, vertebroplasty

2013 Docetaxel, bisphosphonates

2015 Abiraterone

2018 EBRT for multiple bone sites

2019 Radium-223

2020 Cabazitaxel



2021 Enzalutamide

12/2021 PSMA-positive metastatic lesions determined with 68Ga-PSMA-11 PET-CT imaging




03/2022 - 01/2023 6 cycles of RLТ

7,4 GBq every 6 weeks if possible, plus protocol-permitted standard care



Sept 2023



- ✓ Improvement in clinical status and skeletal pain --> no change in pain therapy in this period
- ✓ Only mild dry mouth reported as toxicity
- ✓ Normal renal function
- ✓ Mild lymphocytopenia during the treatment, resolved three months after its conclusion.



Progression of disease occurred 8 months after the last cycle of ^{177}Lu -PSMA-617